Adipose tissue-derived FABP4 mediates glucagon-stimulated hepatic glucose production in gestational diabetes.
cellular research
cohort study
glucagon
insulin resistance
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
14
06
2023
received:
07
05
2023
accepted:
26
06
2023
medline:
4
10
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
One of the most common complications of pregnancy is gestational diabetes mellitus (GDM), which may result in significant health threats of the mother, fetus and the newborn. Fatty acid-binding protein 4 (FABP4) is an adipokine that regulates glucose homeostasis by promoting glucose production and liver insulin resistance in mouse models. FABP4 levels are increased in GDM and correlates with maternal indices of insulin resistance, with a rapid decline post-partum. We therefore aimed to determine the tissue origin of elevated circulating FABP4 levels in GDM and to assess its potential contribution in promoting glucagon-induced hepatic glucose production. FABP4 protein and gene expression was determined in biopsies from placenta, subcutaneous (sWAT) and visceral (vWAT) white adipose tissues from GDM and normoglycaemic pregnant women. FABP4 differential contribution in glucagon-stimulated hepatic glucose production was tested in conditioned media before and after its immune clearance. We showed that FABP4 is expressed in placenta, sWAT and vWAT of pregnant women at term, with a significant increase in its secretion from vWAT of women with GDM compared with normoglycaemic pregnant women. Neutralizing FABP4 from both normoglycaemic pregnant women and GDM vWAT secretome, resulted in a decrease in glucagon-stimulated hepatic glucose production. This study provides new insights into the role of adipose tissue-derived FABP4 in GDM, highlighting this adipokine, as a potential co-activator of glucagon-stimulated hepatic glucose production during pregnancy.
Substances chimiques
Adipokines
0
FABP4 protein, human
0
Fatty Acid-Binding Proteins
0
Glucagon
9007-92-5
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3192-3201Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Newbern D, Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):409-416. doi:10.1097/MED.0b013e32834c800d
Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27(2):89-94. doi:10.5830/CVJA-2016-021
Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):1-21. doi:10.3390/ijms19113342
O'Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA. 1982;248(8):949-952.
Dudzik D, Zorawski M, Skotnicki M, et al. Metabolic fingerprint of gestational diabetes mellitus. J Proteomics. 2014;103:57-71. doi:10.1016/j.jprot.2014.03.025
Wang H, Li N, Chivese T, et al. IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by international association of diabetes in pregnancy study group's criteria. Diabetes Res Clin Pract. 2022;183:109050. doi:10.1016/j.diabres.2021.109050
Mazaki-Tovi S, Kanety H, Pariente C, et al. Insulin sensitivity in late gestation and early postpartum period: the role of circulating maternal adipokines. Gynecol Endocrinol. 2011;27(9):725-731. doi:10.3109/09513590.2010.500426
Francis EC, Li M, Hinkle SN, et al. Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort. BMJ Open Diabetes Res Care. 2020;8(1):e001333. doi:10.1136/bmjdrc-2020-001333
Nguyen-Ngo C, Jayabalan N, Haghvirdizadeh P, Salomon C, Lappas M. Role of adipose tissue in regulating fetal growth in gestational diabetes mellitus. Placenta. 2020;102:39-48. doi:10.1016/j.placenta.2020.05.006
Šimják P, Anderlová K, Cinkajzlová A, Pařízek A, Kršek M, Haluzík M. The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus. Minerva Endocrinol. 2020;45(3):228-242. doi:10.23736/S0391-1977.20.03192-2
Sun J, Zhang D, Xu J, et al. Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis. Lipids Health Dis. 2020;19(1):199. doi:10.1186/s12944-020-01365-w
de Gennaro G, Palla G, Battini L, et al. The role of adipokines in the pathogenesis of gestational diabetes mellitus. Gynecol Endocrinol. 2019;35(9):737-751. doi:10.1080/09513590.2019.1597346
Cao H, Sekiya M, Ertunc ME, et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 2013;17(5):768-778. doi:10.1016/j.cmet.2013.04.012
Gargari P, Mukhopadhyay P, Saboo B, Misra A, Ghosh S. Fabkin and glucose homeostasis. Diabetes Metab Syndr. 2022;16(8):102565. doi:10.1016/j.dsx.2022.102565
Zhong C-Q, Zhang X-P, Ma N, et al. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Med. 2018;7(6):2629-2640. doi:10.1002/cam4.1511
Prentice KJ, Saksi J, Hotamisligil GS. Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses. J Lipid Res. 2019;60(4):734-740. doi:10.1194/jlr.S091793
Furuhashi M, Fuseya T, Murata M, et al. Local production of fatty acid-binding protein 4 in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):825-834. doi:10.1161/ATVBAHA.116.307225
Makowski L, Hotamisligil GS. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J Nutr. 2004;134(9):2464S-2468S. doi:10.1093/jn/134.9.2464S
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274(5291):1377-1379. doi:10.1126/science.274.5291.1377
Burak MF, Inouye KE, White A, et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med. 2015;7(319):319ra205. doi:10.1126/scitranslmed.aac6336
Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 2000;141(9):3388-3396. doi:10.1210/endo.141.9.7637
Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52(3):405-413. doi:10.1373/clinchem.2005.062463
von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012;32(9):2327-2335. doi:10.1161/ATVBAHA.112.248609
Tso AWK, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30(10):2667-2672. doi:10.2337/dc07-0413
Kaess BM, Enserro DM, McManus DD, et al. Cardiometabolic correlates and heritability of fetuin-a, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham heart study. J Clin Endocrinol Metab. 2012;97(10):E1943-E1947. doi:10.1210/jc.2012-1458
Ron I, Lerner RK, Rathaus M, et al. The adipokine FABP4 is a key regulator of neonatal glucose homeostasis. JCI Insight. 2021;6(20):1-13. doi:10.1172/jci.insight.138288
Kralisch S, Stepan H, Kratzsch J, et al. Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus. Eur J Endocrinol. 2009;160(1):33-38. doi:10.1530/EJE-08-0540
Li Y, Xiao R, Li C, Huangfu J, Mao J. Increased plasma levels of FABP4 and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus. Med Sci Monit. 2015;21:426-431. doi:10.12659/MSM.892431
Ning H, Tao H, Weng Z, Zhao X. Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus. Acta Diabetol. 2016;53(6):891-898. doi:10.1007/s00592-016-0867-8
Zhang Y, Zhang H-H, Lu J-H, et al. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. J Diabetes Investig. 2016;7(5):797-804. doi:10.1111/jdi.12484
Vorobjova T, Tagoma A, Talja I, Janson H, Kirss A, Uibo R. FABP4 and I-FABP levels in pregnant women are associated with body mass index but not gestational diabetes. J Diabetes Res. 2022;2022:1089434. doi:10.1155/2022/1089434
American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. doi:10.1097/AOG.0000000000002501
Severgnini M, Sherman J, Sehgal A, et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. Cytotechnology. 2012;64(2):187-195. doi:10.1007/s10616-011-9407-0
Ertunc ME, Sikkeland J, Fenaroli F, et al. Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res. 2015;56(2):423-434. doi:10.1194/jlr.M055798
Inouye KE, Prentice KJ, Lee A, et al. Endothelial FABP4 constitutes the majority of basal circulating hormone levels and regulates lipolysis-driven insulin secretion. JCI Insight. 2023. Online ahead of print. doi:10.1172/jci.insight.164642
Li L, Lee SJ, Kook SY, Ahn TG, Lee JY, Hwang JY. Serum from pregnant women with gestational diabetes mellitus increases the expression of FABP4 mRNA in primary subcutaneous human pre-adipocytes. Obstet Gynecol Sci. 2017;60(3):274-282. doi:10.5468/ogs.2017.60.3.274
Tirosh A, Calay ES, Tuncman G, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med. 2019;11(489):1-13. doi:10.1126/scitranslmed.aav0120
Gruber N, Rathaus M, Ron I, et al. Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes. Diabetologia. 2022;65(2):366-374. doi:10.1007/s00125-021-05606-0
Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2014;8(Suppl 3):23-33. doi:10.4137/CMC.S17067
Drolet R, Richard C, Sniderman AD, et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond). 2008;32(2):283-291. doi:10.1038/sj.ijo.0803708
Fisher RM, Eriksson P, Hoffstedt J, et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001;44(10):1268-1273. doi:10.1007/s001250100643
Clemente-Postigo M, Queipo-Ortuño MI, Fernandez-Garcia D, Gomez-Huelgas R, Tinahones FJ, Cardona F. Adipose tissue gene expression of factors related to lipid processing in obesity. PLoS One. 2011;6(9):e24783. doi:10.1371/journal.pone.0024783
Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, et al. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One. 2012;7(11):e48605. doi:10.1371/journal.pone.0048605
Liljenquist JE, Bomboy JD, Lewis SB, et al. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest. 1974;53(1):190-197. doi:10.1172/JCI107537
Qiao G-H, Sun X-Z. Increased plasma fatty acid binding protein 4 concentration at the first prenatal visit and its relevance to preeclampsia. Hypertens Res. 2018;41(9):763-769. doi:10.1038/s41440-018-0064-y
Li B, Yang H, Zhang W, et al. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. PLoS One. 2018;13(2):e0192347. doi:10.1371/journal.pone.0192347
Fasshauer M, Seeger J, Waldeyer T, et al. Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens. 2008;21(5):582-586. doi:10.1038/ajh.2008.23
Scifres CM, Catov JM, Simhan H. Maternal serum fatty acid binding protein 4 (FABP4) and the development of preeclampsia. J Clin Endocrinol Metab. 2012;97(3):E349-E356. doi:10.1210/jc.2011-2276